Soy isoflavones

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Soy isoflavones
DrugBank Accession Number
DB14101
Background

Not Available

Type
Small Molecule
Groups
Approved, Experimental
Synonyms
  • Soy germ isoflavones
  • Soybean isoflavones
  • Soybean isoflavoues

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofMenopausal hot flashes•••••••••••••••••••• ••••••• ••••••• •••• ••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Solgen 40
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
CALCIBON D SOYA FORTE TABLETASSoy isoflavones (50 mg) + Calcium citrate tetrahydrate (950 mg) + Cholecalciferol (400 IU) + Magnesium oxide (50 mg)TabletOralALTEA FARMACEUTICA S.A.2012-10-12Not applicableColombia flag
Cheon Shim Bo YunSoy isoflavones (30 mg/1) + D-alpha-Tocopherol acetate (3 mg/1) + N-Acetylglucosamine (263 mg/1)CapsuleOralSaimdang Cosmetics Co., Ltd2010-11-08Not applicableUS flag
D-Cal SoyCalSoy isoflavones (1 g/1) + Calcium carbonate (28.32 g/1) + Cholecalciferol (480 ug/1)TabletOralA&Z Pharmaceutical, Inc.2010-01-222018-11-01US flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Cheon Shim Bo YunSoy isoflavones (30 mg/1) + D-alpha-Tocopherol acetate (3 mg/1) + N-Acetylglucosamine (263 mg/1)CapsuleOralSaimdang Cosmetics Co., Ltd2010-11-08Not applicableUS flag

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
71B37NR06D
CAS number
Not Available

References

General References
Not Available
Wikipedia
Soybean

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedBasic ScienceDrug Drug Interaction (DDI)1
4CompletedTreatmentHot Flashes1
4Unknown StatusTreatmentPostmenopausal Women With Moderate Vasomotor Symptoms1
2CompletedTreatmentRecurrent Hypopharyngeal Squamous Cell Carcinoma / Recurrent Laryngeal Squamous Cell Carcinoma / Recurrent Oropharyngeal Squamous Cell Carcinoma / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Stage 1 Oropharyngeal Squamous Cell Carcinoma (OPSCCA) / Stage I Squamous Cell Carcinoma of the Hypopharynx / Stage I Squamous Cell Carcinoma of the Larynx / Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage I Verrucous Carcinoma of the Larynx / Stage I Verrucous Carcinoma of the Oral Cavity / Stage II Hypopharyngeal Squamous Cell Carcinoma / Stage II Laryngeal Squamous Cell Carcinoma / Stage II Laryngeal Verrucous Carcinoma / Stage II Oral Cavity Verrucous Carcinoma / Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage II Squamous Cell Carcinoma of the Oropharynx / Stage III Hypopharyngeal Squamous Cell Carcinoma / Stage III Laryngeal Verrucous Carcinoma / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage III Verrucous Carcinoma of the Oral Cavity / Stage IV Hypopharyngeal Squamous Cell Carcinoma / Stage IVA Squamous Cell Carcinoma of the Larynx / Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVA Verrucous Carcinoma of the Larynx / Stage IVA Verrucous Carcinoma of the Oral Cavity / Tongue Carcinoma1
2CompletedTreatmentRenal Failure, Chronic Renal Failure1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet, film coatedOral80 mg
Tablet, coatedOral80 mg
CapsuleOral
TabletOral
Capsule, coatedOral117.85 mg
Tablet, coatedOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at June 20, 2018 15:19 / Updated at June 12, 2020 16:53